Skip to main content

Research Repository

Advanced Search

Plasma cells: a feasible therapeutic target in pulmonary fibrosis?

Goodwin, Amanda T.; Noble, Paul W.; Tatler, Amanda L.


Clinical Assistant Professor (Nihr Clinical Lecturer in Respiratory Medicine)

Paul W. Noble

Principal Research Fellow


Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterised by the irreversible replacement of normal lung parenchyma with stiff scar tissue. The prognosis of IPF is very poor, with a median survival worse than many cancers at 2–3 years, and this condition is associated with increasing incidence and mortality rates worldwide [1–4]. Despite a dramatic increase in IPF clinical trials over the past 20 years, there remain only two therapies approved for use in IPF: nintedanib and pirfenidone [5, 6]. These antifibrotic drugs are not curative, do not improve patient symptoms or functional status and only slow down loss of lung function. Therefore, work to understand the key cells and molecular pathways that drive IPF is essential to identify new therapies for this devastating disease.


Goodwin, A. T., Noble, P. W., & Tatler, A. L. (2022). Plasma cells: a feasible therapeutic target in pulmonary fibrosis?. European Respiratory Journal, 60(5), Article 2201748.

Journal Article Type Article
Acceptance Date Sep 17, 2022
Online Publication Date Nov 24, 2022
Publication Date Nov 24, 2022
Deposit Date Dec 18, 2022
Journal European Respiratory Journal
Print ISSN 0903-1936
Electronic ISSN 1399-3003
Publisher European Respiratory Society (ERS)
Peer Reviewed Peer Reviewed
Volume 60
Issue 5
Article Number 2201748
Keywords Pulmonary and Respiratory Medicine
Public URL
Publisher URL